Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: RealMuLan who wrote (2128)	11/14/2008 6:55:27 PM
From: RealMuLan	Respond to of 2173

Institution dumping investorvillage.com

To: RealMuLan who wrote (2128)	11/16/2008 3:18:27 PM
From: RealMuLan	Read Replies (1) \| Respond to of 2173

Amylin Builds on the Success of Byetta Minor Label Changes and Approval of Once Weekly Version of Drug Are Anticipated Querida Anderson Nov 15 2008 (Vol. 28, No. 20) genengnews.com

To: RealMuLan who wrote (2128)	11/5/2009 3:15:52 PM
From: RealMuLan	Respond to of 2173

Amylin To Live Large On The Fat Of The Land John Dobosz, 11.05.09, 01:50 PM EST forbes.com There's a lot of crossover between so-called obesity drugs and diabetes treatments. Amylin has both of them covered. According to the American Diabetes Association, 23.6 million children and adults in the U.S., or 7.8% of the population, have diabetes, with 1.6 million new cases diagnosed in people aged 20 years and older each year. Among those 60 and older, the prevalence of the chronic condition jumps to 23.1%, and diabetes was the seventh leading cause of death listed on U.S. death certificates in 2006. Diabetes, a disease in which the body fails to produce insulin or to process it properly, was responsible for $116 billion in direct medical costs in the U.S. in 2007. ...